Heather Whitehouse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heather Whitehouse has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Alison Margaret Layton
Skin Research Centre, Hull York Medical School, University of York, York, UK
2 shared publications - Elizabeth Anne Eady
Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, UK
2 shared publications Mark Wilkinson
Department of Dermatology, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
2 shared publicationsA.M. Layton
Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, U.K.
1 shared publication- Adam Fityan
Dermatology Department University Hospital, Southampton NHS Foundation Trust Southampton UK
1 shared publication Adam Haworth
St Mary's Hospital Portsmouth UK
1 shared publication
Latest Publications
- 26 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (6) , 491-496
Sensitisation to the acrylate co‐polymers glyceryl acrylate/acrylic acid co‐polymer, sodium polyacrylate and acrylates/C10‐30 alkyl acrylate cross‐polymer (Carbopol®) is rare
Background: Acrylate polymers and cross‐polymers (ACPs) are frequently used cosmetic ingredients. The British Society for Cutaneous Allergy (BSCA) and the UK Cosmetic, Toiletry and Perfumery Association (CTPA) collaborated to investigate the allergenic potential of three commonly‐used ACPs.Objectives: The objective of this study is to determine the prevalence of allergic contact dermatitis (ACD) to three ACPs: glyceryl acrylate/acrylic acid co‐polymer, sodium polyacrylate, and acrylates/C10‐30 alkyl acrylate cross‐polymer (Carbopol®).Materials and Methods: The BSCA prospectively audited data collected from 20 centres in the UK and Ireland between 1st September 2021 and 1st September 2022. Patients with suspected ACD to (meth)acrylates, with facial dermatitis, or consecutive patients, were patch tested to glyceryl acrylate/acrylic acid co‐polymer 10% aqueous (aq.) sodium polyacrylate 2% aq., and to acrylates/C10‐30 alkyl acrylate cross‐polymer 2% aq. (Carbopol®). The frequencies of positive, irritant, and doubtful reactions were recorded.Results: In total, 1302 patients were patch tested. To glyceryl acrylate/acrylic acid co‐polymer, there was one doubtful reaction in a patient allergic to multiple (meth)acrylates, and one irritant. To sodium polyacrylate, there were four irritant reactions, one doubtful, and one positive reaction; in all cases, relevance was unknown and there was no demonstrable (meth)acrylate allergy. There were no reactions to Carbopol®.Conclusions: Sensitisation to these concentrations of the three tested ACPs is rare. Elicitation of dermatitis in (meth)acrylate‐sensitised patients by exposure to these three ACPs appears unlikely.
- 26 August 2024
- Published by Wiley in Contact Dermatitis
- Vol. 91 (6) , 491-496
Sensitisation to the acrylate co‐polymers glyceryl acrylate/acrylic acid co‐polymer, sodium polyacrylate and acrylates/C10‐30 alkyl acrylate cross‐polymer (Carbopol®) is rare
Background: Acrylate polymers and cross‐polymers (ACPs) are frequently used cosmetic ingredients. The British Society for Cutaneous Allergy (BSCA) and the UK Cosmetic, Toiletry and Perfumery Association (CTPA) collaborated to investigate the allergenic potential of three commonly‐used ACPs.Objectives: The objective of this study is to determine the prevalence of allergic contact dermatitis (ACD) to three ACPs: glyceryl acrylate/acrylic acid co‐polymer, sodium polyacrylate, and acrylates/C10‐30 alkyl acrylate cross‐polymer (Carbopol®).Materials and Methods: The BSCA prospectively audited data collected from 20 centres in the UK and Ireland between 1st September 2021 and 1st September 2022. Patients with suspected ACD to (meth)acrylates, with facial dermatitis, or consecutive patients, were patch tested to glyceryl acrylate/acrylic acid co‐polymer 10% aqueous (aq.) sodium polyacrylate 2% aq., and to acrylates/C10‐30 alkyl acrylate cross‐polymer 2% aq. (Carbopol®). The frequencies of positive, irritant, and doubtful reactions were recorded.Results: In total, 1302 patients were patch tested. To glyceryl acrylate/acrylic acid co‐polymer, there was one doubtful reaction in a patient allergic to multiple (meth)acrylates, and one irritant. To sodium polyacrylate, there were four irritant reactions, one doubtful, and one positive reaction; in all cases, relevance was unknown and there was no demonstrable (meth)acrylate allergy. There were no reactions to Carbopol®.Conclusions: Sensitisation to these concentrations of the three tested ACPs is rare. Elicitation of dermatitis in (meth)acrylate‐sensitised patients by exposure to these three ACPs appears unlikely.
- 9 June 2023
- Published by Wiley in Contact Dermatitis
- Vol. 89 (3) , 205-206
Contact sensitisation to shellac: A possible marker of fragrance allergy
- 9 June 2023
- Published by Wiley in Contact Dermatitis
- Vol. 89 (3) , 205-206
Contact sensitisation to shellac: A possible marker of fragrance allergy
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 295-308
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022
Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.
- 1 September 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (3) , 295-308
British Association of Dermatologists and British Photodermatology Group guidelines for narrowband ultraviolet B phototherapy 2022
Linked Comment: P. Wolf. Br J Dermatol 2022; 187:285–286.
- 1 April 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (2) , 52-66
Updated Criteria to Include Contact Allergens in the European Baseline Series With Suggested Additions
- 1 April 2022
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 9 (2) , 52-66
Updated Criteria to Include Contact Allergens in the European Baseline Series With Suggested Additions
- 8 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (8) , 1495-1503
MicroRNAs as biomarkers of atrophic scarring in acne: a cross‐sectional analysis of 41 patients
Background Acne is the commonest inflammatory dermatosis seen worldwide. Atrophic acne scarring is a frequent complication, arising from acne of any severity. MicroRNAs (miRNA) are non-coding RNA molecules of 19 to 25 nucleotides that function as post-transcriptomic mediators of gene expression. They have demonstrated differential expression in various pathologies, such as eczema and psoriasis, allowing for a unique miRNA “signature” profile to be established for different disease states. Aim To establish a miRNA signature for acne, and acne-associated atrophic scarring and to identify if a pattern of circulating miRNA is evident in patients who are prone to scarring. Methods Forty-one participants were consecutively recruited to this study. Circulating miRNA was quantified from plasma samples in all 41 patients. In 8 patients, and a further validation cohort of 9 patients, whole microRNAome was undertaken from tissue specimens which included lesional, normal, and where present, scarred skin. Results Three miRNAs, miR-223, miR-21 and miR-150 were statistically significantly overexpressed in acne lesions, and notably, in clinically uninvolved skin in participants prone to scarring. In this subgroup, we also found statistically significantly elevated levels of circulating miRNA-21 and miRNA-150. Conclusion The presence of elevated levels of these specific miRNAs in the serum of patients with acne raises the potential of a blood test to identify those at risk of scarring, allowing for earlier intervention with effective therapy.
- 8 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (8) , 1495-1503
MicroRNAs as biomarkers of atrophic scarring in acne: a cross‐sectional analysis of 41 patients
Background Acne is the commonest inflammatory dermatosis seen worldwide. Atrophic acne scarring is a frequent complication, arising from acne of any severity. MicroRNAs (miRNA) are non-coding RNA molecules of 19 to 25 nucleotides that function as post-transcriptomic mediators of gene expression. They have demonstrated differential expression in various pathologies, such as eczema and psoriasis, allowing for a unique miRNA “signature” profile to be established for different disease states. Aim To establish a miRNA signature for acne, and acne-associated atrophic scarring and to identify if a pattern of circulating miRNA is evident in patients who are prone to scarring. Methods Forty-one participants were consecutively recruited to this study. Circulating miRNA was quantified from plasma samples in all 41 patients. In 8 patients, and a further validation cohort of 9 patients, whole microRNAome was undertaken from tissue specimens which included lesional, normal, and where present, scarred skin. Results Three miRNAs, miR-223, miR-21 and miR-150 were statistically significantly overexpressed in acne lesions, and notably, in clinically uninvolved skin in participants prone to scarring. In this subgroup, we also found statistically significantly elevated levels of circulating miRNA-21 and miRNA-150. Conclusion The presence of elevated levels of these specific miRNAs in the serum of patients with acne raises the potential of a blood test to identify those at risk of scarring, allowing for earlier intervention with effective therapy.
- 2 September 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (2) , 95-102
Formaldehyde 2% is not a useful means of detecting allergy to formaldehyde releasers— results of theESSCAnetwork, 2015‐2018
Background: Studies suggest that patch testing with formaldehyde releasers (FRs) gives significant additional information to formaldehyde 1% aq. and should be considered for addition to the European baseline series (EBS). It is not known if this is also true for formaldehyde 2% aq.Objectives: To determine the frequency of sensitization to formaldehyde 2% aq. and co‐reactivity with FRs. To establish whether there is justification for including FRs in the EBS.Materials and Methods: A 4‐year, multi‐center retrospective analysis of patients with positive patch test reactions to formaldehyde 2% aq. and five FRs.Results: A maximum of 15 067 patients were tested to formaldehyde 2% aq. and at least one FR. The percentage of isolated reactions to FR, without co‐reactivity to, formaldehyde 2% aq. for each FR were: 46.8% for quarternium‐15 1% pet.; 67.4% imidazolidinyl urea 2% pet.; 64% diazolidinyl urea 2% pet.; 83.3% 1,3‐dimethylol‐5, 5‐dimethyl hydantoin (DMDM) hydantoin 2% pet. and 96.3% 2‐bromo‐2‐nitropropane‐1,3‐diol 0.5% pet. This demonstrates that co‐reactivity varies between FRs and formaldehyde, from being virtually non‐existent in 2‐bromo‐2‐nitropropane‐1,3‐diol 0.5% pet. (Cohen's kappa: 0, 95% confidence interval [CI] −0.02 to 0.02)], to only weak concordance for quaternium‐15 [Cohen's kappa: 0.22, 95%CI 0.16 to 0.28)], where Cohen's kappa value of 1 would indicate full concordance.Conclusions: Formaldehyde 2% aq. is an inadequate screen for contact allergy to the formaldehyde releasers, which should be considered for inclusion in any series dependant on the frequency of reactions to and relevance of each individual allergen.
- 2 September 2020
- Published by Wiley in Contact Dermatitis
- Vol. 84 (2) , 95-102
Formaldehyde 2% is not a useful means of detecting allergy to formaldehyde releasers— results of theESSCAnetwork, 2015‐2018
Background: Studies suggest that patch testing with formaldehyde releasers (FRs) gives significant additional information to formaldehyde 1% aq. and should be considered for addition to the European baseline series (EBS). It is not known if this is also true for formaldehyde 2% aq.Objectives: To determine the frequency of sensitization to formaldehyde 2% aq. and co‐reactivity with FRs. To establish whether there is justification for including FRs in the EBS.Materials and Methods: A 4‐year, multi‐center retrospective analysis of patients with positive patch test reactions to formaldehyde 2% aq. and five FRs.Results: A maximum of 15 067 patients were tested to formaldehyde 2% aq. and at least one FR. The percentage of isolated reactions to FR, without co‐reactivity to, formaldehyde 2% aq. for each FR were: 46.8% for quarternium‐15 1% pet.; 67.4% imidazolidinyl urea 2% pet.; 64% diazolidinyl urea 2% pet.; 83.3% 1,3‐dimethylol‐5, 5‐dimethyl hydantoin (DMDM) hydantoin 2% pet. and 96.3% 2‐bromo‐2‐nitropropane‐1,3‐diol 0.5% pet. This demonstrates that co‐reactivity varies between FRs and formaldehyde, from being virtually non‐existent in 2‐bromo‐2‐nitropropane‐1,3‐diol 0.5% pet. (Cohen's kappa: 0, 95% confidence interval [CI] −0.02 to 0.02)], to only weak concordance for quaternium‐15 [Cohen's kappa: 0.22, 95%CI 0.16 to 0.28)], where Cohen's kappa value of 1 would indicate full concordance.Conclusions: Formaldehyde 2% aq. is an inadequate screen for contact allergy to the formaldehyde releasers, which should be considered for inclusion in any series dependant on the frequency of reactions to and relevance of each individual allergen.
- 1 August 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (6) , 732-733
A regional audit of symptomatic erythema rates in psoriasis patients treated with whole-body narrowband ultraviolet type B: a basis for setting an erythema standard
Erythema is the commonest adverse event caused by ultraviolet radiation (UVR) therapy and is characterised by redness often with discomfort and if severe, oedema and blistering. This peaks at 12‐to‐24 hours after exposure and persists for up‐to 72 hours. In clinical practice, erythema is assessed subjectively and recorded using a semi‐quantitative grading system consisting of E0 (no erythema), E1 (barely perceptible asymptomatic), E2 (well defined with mild discomfort), E3 (well defined and painful) to E4 (painful erythema, with bullae).
- 1 August 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (6) , 732-733
A regional audit of symptomatic erythema rates in psoriasis patients treated with whole-body narrowband ultraviolet type B: a basis for setting an erythema standard
Erythema is the commonest adverse event caused by ultraviolet radiation (UVR) therapy and is characterised by redness often with discomfort and if severe, oedema and blistering. This peaks at 12‐to‐24 hours after exposure and persists for up‐to 72 hours. In clinical practice, erythema is assessed subjectively and recorded using a semi‐quantitative grading system consisting of E0 (no erythema), E1 (barely perceptible asymptomatic), E2 (well defined with mild discomfort), E3 (well defined and painful) to E4 (painful erythema, with bullae).
- 21 October 2017
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (1) , 65-66
Traumatic subungual neuroma
- 21 October 2017
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 43 (1) , 65-66
Traumatic subungual neuroma
- Open Access
- 24 May 2017
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 10 (3) , 163-170
Prioritizing treatment outcomes: How people with acne vulgaris decide if their treatment is working
To collect information about how people with acne make day-to-day decisions concerning the effectiveness of their treatment. Between May and August 2013, an optional question was embedded in the James Lind Alliance Acne Priority Setting Partnership's online survey to collect treatment uncertainties. The question asked people with acne to “Tell us in your own words how you decide if your treatment has been effective.” A total of 742 respondents specified at least one outcome or means of assessing change (outcome measure). Fewer spots were the most commonly cited outcome, identified by 272 respondents (36.7%). Other frequently mentioned outcomes were in descending order: less redness (19.4%), reduction in spot size (12.1%), and less pain/discomfort (11.4%). Signs were much more commonly used than symptoms and surrogate outcomes such as changes in aspects of life quality were infrequently mentioned. Visual inspection of the skin was the most widely adopted outcome measure (16.3%). Although the most frequently used methods map well onto the outcome measures adopted in the majority of acne trials, namely physician-assessed changes in lesion counts and global acne severity, people with acne often take into account several factors that cannot be assessed by a third party at a single point in time. The minimal use of changes in psychosocial wellbeing and mood may reflect that these are regarded as secondary consequences of improvements in appearance. The robustness of these findings now requires independent evaluation. If confirmed, they could form the basis of a new patient-reported outcome measure.
- 24 May 2017
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 10 (3) , 163-170
Open AccessPrioritizing treatment outcomes: How people with acne vulgaris decide if their treatment is working
To collect information about how people with acne make day-to-day decisions concerning the effectiveness of their treatment. Between May and August 2013, an optional question was embedded in the James Lind Alliance Acne Priority Setting Partnership's online survey to collect treatment uncertainties. The question asked people with acne to “Tell us in your own words how you decide if your treatment has been effective.” A total of 742 respondents specified at least one outcome or means of assessing change (outcome measure). Fewer spots were the most commonly cited outcome, identified by 272 respondents (36.7%). Other frequently mentioned outcomes were in descending order: less redness (19.4%), reduction in spot size (12.1%), and less pain/discomfort (11.4%). Signs were much more commonly used than symptoms and surrogate outcomes such as changes in aspects of life quality were infrequently mentioned. Visual inspection of the skin was the most widely adopted outcome measure (16.3%). Although the most frequently used methods map well onto the outcome measures adopted in the majority of acne trials, namely physician-assessed changes in lesion counts and global acne severity, people with acne often take into account several factors that cannot be assessed by a third party at a single point in time. The minimal use of changes in psychosocial wellbeing and mood may reflect that these are regarded as secondary consequences of improvements in appearance. The robustness of these findings now requires independent evaluation. If confirmed, they could form the basis of a new patient-reported outcome measure.